These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2181121)

  • 21. Continuous infusion of ticarcillin-clavulanate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacodynamics.
    Munckhof WJ; Carney J; Neilson G; Neilson J; Carroll J; McWhinney B; Whitby M
    Int J Antimicrob Agents; 2005 Jun; 25(6):514-22. PubMed ID: 15878264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacology of clavulanic acid and ticarcillin combined.
    Scully BE; Steinman R; Chin NX; Neu HC
    Chemioterapia; 1984 Dec; 3(6):385-9. PubMed ID: 6529781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of ticarcillin/clavulanate potassium in the treatment of obstetric and gynecologic infections.
    Martens MG
    Hosp Formul; 1990 Feb; 25(2):186-8, 192. PubMed ID: 10113105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ticarcillin/clavulanate for treatment of postpartum endometritis.
    Faro S; Hammill HA; Maccato M; Martens M
    Rev Infect Dis; 1991; 13 Suppl 9():S758-62. PubMed ID: 1925321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
    Hou F; Li J; Gao L; Chen Y
    Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibacterial activity of ticarcillin in the presence of clavulanate potassium.
    Sutherland R; Beale AS; Boon RJ; Griffin KE; Slocombe B; Stokes DH; White AR
    Am J Med; 1985 Nov; 79(5B):13-24. PubMed ID: 3878080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New antimicrobial agent series XXXVII: potassium clavulanate/Ticarcillin sodium].
    Fujimori I
    Jpn J Antibiot; 1991 Apr; 44(4):365-87. PubMed ID: 1880918
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of ticarcillin and ticarcillin/clavulanic acid on the in-vitro activity of human granulocytes against beta-lactamase-producing Klebsiella pneumoniae.
    Cuffini AM; de Renzi G; Tullio V; Paizis G; Carlone NA
    Int J Tissue React; 1995; 17(5-6):199-203. PubMed ID: 8835630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of ticarcillin plus clavulanic acid with cefoxitin in the treatment of female pelvic infection.
    Pastorek JG; Aldridge KE; Cunningham GL; Faro S; Graffeo S; McNeeley GS; Tan JS
    Am J Med; 1985 Nov; 79(5B):161-3. PubMed ID: 4073084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ticarcillin plus clavulanic acid in the treatment of patients with cancer.
    Fainstein V; Elting L; Pitlik S; Hortobagyi G; Keating M; Bodey GP
    Am J Med; 1985 Nov; 79(5B):62-6. PubMed ID: 4073096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical evaluation of Augpenin (clavulanic acid-ticarcillin) in urinary tract infections: especially against beta-lactamase producing strains].
    Shiono A; Kurihara J; Hayashi M; Suzuki T; Imai K; Yamanaka H; Takezawa Y; Kiren H; Okabe K; Tomaru Y
    Hinyokika Kiyo; 1993 Aug; 39(8):777-82. PubMed ID: 8379483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vitro study of the effects of a ticarcillin-clavulanic acid combination on Pseudomonas aeruginosa as a function of resistant phenotypes].
    Thabaut A; Meyran M
    Pathol Biol (Paris); 1985 May; 33(5):408-11. PubMed ID: 3929218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro susceptibility of bacteria to a ticarcillin-clavulanic acid combination.
    Sparks SE; Jones RL; Kilgore WR
    Am J Vet Res; 1988 Dec; 49(12):2038-40. PubMed ID: 3239838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implications of beta-lactamase-inhibitor combinations.
    Jones RN
    J Reprod Med; 1988 Jun; 33(6 Suppl):574-8. PubMed ID: 3294402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of ticarcillin disodium plus clavulanate potassium in the management of acute bacterial infections in children.
    Gooch WM; Swenson E; Higbee MD
    Am J Med; 1985 Nov; 79(5B):184-7. PubMed ID: 4073089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parenteral beta-lactamase inhibitor combinations for clinical use.
    Manzella JP
    Am Fam Physician; 1995 May; 51(7):1695-8. PubMed ID: 7754928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beta-lactamase inhibition: therapeutic advances. Proceedings of a symposium. Fort Lauderdale, Florida, March 22-23, 1985.
    Am J Med; 1985 Nov; 79(5B):1-196. PubMed ID: 3878079
    [No Abstract]   [Full Text] [Related]  

  • 38. Bactericidal effects of amoxycillin/clavulanic acid and ticarcillin/clavulanic acid in in-vitro kinetic models.
    White AR; Stokes DH; Slocombe B; Sutherland R
    J Antimicrob Chemother; 1985 Jan; 15 Suppl A():227-32. PubMed ID: 3980328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of CAPD peritonitis with clavulanate potentiated ticarcillin.
    Pasadakis P; Thodis E; Euthimiadou A; Panagoutsos S; Oustoglou E; Kartali S; Vargemezis V
    Adv Perit Dial; 1992; 8():238-41. PubMed ID: 1361796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity and in vivo evaluation of ticarcillin plus clavulanic acid against aerobic and anaerobic bacteria.
    Bansal MB; Chuah SK; Thadepalli H
    Am J Med; 1985 Nov; 79(5B):33-8. PubMed ID: 4073093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.